Valion Bio, Inc. Increase (Decrease) in Accrued Liabilities
Valion Bio, Inc. (VBIO) reported Increase (Decrease) in Accrued Liabilities of $1.46 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilities · last filed 2026-08-14
- Valion Bio, Inc. increase (decrease) in accrued liabilities for the quarter ending 2026-06-30 was $341.00K, a 73.10% increase year-over-year.
- Valion Bio, Inc. increase (decrease) in accrued liabilities for the quarter ending 2026-03-31 was $1.11M, a 614.10% increase year-over-year.
- Valion Bio, Inc. increase (decrease) in accrued liabilities for the quarter ending 2025-12-31 was $209.00K.
- Valion Bio, Inc. increase (decrease) in accrued liabilities for the quarter ending 2025-09-30 was -$327.00K, a 498.78% decline year-over-year.
- Valion Bio, Inc. increase (decrease) in accrued liabilities for fiscal 2025 was $235.00K.
- Valion Bio, Inc. increase (decrease) in accrued liabilities for fiscal 2024 was -$348.00K, a 437.86% decline from fiscal 2023.
- Valion Bio, Inc. increase (decrease) in accrued liabilities for fiscal 2023 was $103.00K, a 5.50% decline from fiscal 2022.
- Valion Bio, Inc. increase (decrease) in accrued liabilities for fiscal 2022 was $109.00K, a 14.84% decline from fiscal 2021.
| Period end | Increase (Decrease) in Accrued Liabilities 1 month | Increase (Decrease) in Accrued Liabilities 3 month | Increase (Decrease) in Accrued Liabilities 6 month | Increase (Decrease) in Accrued Liabilities 9 month | Increase (Decrease) in Accrued Liabilities 12 month | Increase (Decrease) in Accrued Liabilities 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | $341.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $1.46M 10-Q · filed 2026-08-14 | $1.66M derived: sum of 3 quarters · filed 2026-08-14 | $1.34M derived: sum of 4 quarters · filed 2026-08-14 | ||
| 2026-03-31 | $1.11M 10-Q · filed 2026-05-14 | $1.32M derived: sum of 2 quarters · filed 2026-05-14 | $996.00K derived: sum of 3 quarters · filed 2026-05-14 | $1.19M derived: sum of 4 quarters · filed 2026-08-14 | ||
| 2025-12-31 | $209.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$118.00K derived: sum of 2 quarters · filed 2026-03-30 | $79.00K derived: sum of 3 quarters · filed 2026-08-14 | $235.00K 10-K · filed 2026-03-30 | ||
| 2025-09-30 | -$327.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | -$130.00K derived: sum of 2 quarters · filed 2026-08-14 | $26.00K 10-Q · filed 2025-11-14 | -$54.00K derived: sum of 4 quarters · filed 2026-08-14 | ||
| 2025-06-30 | $197.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $353.00K 10-Q · filed 2026-08-14 | $273.00K derived: sum of 3 quarters · filed 2026-08-14 | $355.00K derived: sum of 4 quarters · filed 2026-08-14 | ||
| 2025-03-31 | $156.00K 10-Q · filed 2026-05-14 | $76.00K derived: sum of 2 quarters · filed 2026-05-14 | $158.00K derived: sum of 3 quarters · filed 2026-05-14 | $38.00K derived: sum of 4 quarters · filed 2026-05-14 | ||
| 2024-12-31 | -$80.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $2.00K derived: sum of 2 quarters · filed 2026-03-30 | -$118.00K derived: sum of 3 quarters · filed 2026-03-30 | -$348.00K 10-K · filed 2026-03-30 | ||
| 2024-09-30 | $82.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | -$38.00K derived: sum of 2 quarters · filed 2025-11-14 | -$268.00K 10-Q · filed 2025-11-14 | $19.00K derived: sum of 4 quarters · filed 2025-11-14 | ||
| 2024-06-30 | -$120.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$350.00K 10-Q · filed 2025-08-14 | -$63.00K derived: sum of 3 quarters · filed 2025-08-14 | -$18.00K derived: sum of 4 quarters · filed 2025-08-14 | ||
| 2024-03-31 | -$230.00K 10-Q · filed 2025-05-15 | $57.00K derived: sum of 2 quarters · filed 2025-05-15 | $102.00K derived: sum of 3 quarters · filed 2025-05-15 | -$51.00K derived: sum of 4 quarters · filed 2025-05-15 | ||
| 2023-12-31 | $287.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-21 | $332.00K derived: sum of 2 quarters · filed 2025-03-21 | $179.00K derived: sum of 3 quarters · filed 2025-03-21 | $103.00K 10-K · filed 2025-03-21 | ||
| 2023-09-30 | $45.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | -$108.00K derived: sum of 2 quarters · filed 2024-11-14 | -$184.00K 10-Q · filed 2024-11-14 | -$69.00K derived: sum of 4 quarters · filed 2024-11-14 | ||
| 2023-06-30 | -$153.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | -$229.00K 10-Q · filed 2024-08-14 | -$114.00K derived: sum of 3 quarters · filed 2024-08-14 | -$146.00K derived: sum of 4 quarters · filed 2024-08-14 | ||
| 2023-03-31 | -$76.00K 10-Q · filed 2024-05-15 | $39.00K derived: sum of 2 quarters · filed 2024-05-15 | $7.00K derived: sum of 3 quarters · filed 2024-05-15 | -$3.00K derived: sum of 4 quarters · filed 2024-05-15 | ||
| 2022-12-31 | $115.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | $83.00K derived: sum of 2 quarters · filed 2024-03-25 | $73.00K derived: sum of 3 quarters · filed 2024-03-25 | $109.00K 10-K · filed 2024-03-25 | $106.00K 10-K · filed 2023-03-31 | |
| 2022-09-30 | -$32.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | -$42.00K derived: sum of 2 quarters · filed 2023-11-14 | -$6.00K 10-Q · filed 2023-11-14 | -$45.00K derived: sum of 4 quarters · filed 2023-11-14 | ||
| 2022-06-30 | -$10.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $26.00K 10-Q · filed 2023-08-14 | -$13.00K derived: sum of 3 quarters · filed 2023-08-14 | -$6.00K derived: sum of 4 quarters · filed 2023-08-14 | ||
| 2022-03-31 | $36.00K 10-Q · filed 2023-05-15 | -$3.00K derived: sum of 2 quarters · filed 2023-05-15 | $4.00K derived: sum of 3 quarters · filed 2023-05-15 | -$6.00K derived: sum of 4 quarters · filed 2023-05-15 | ||
| 2022-01-31 | $36.00K 10-Q · filed 2022-05-16 | |||||
| 2021-12-31 | -$39.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | -$32.00K derived: sum of 2 quarters · filed 2023-03-31 | -$42.00K derived: sum of 3 quarters · filed 2023-03-31 | $128.00K 10-K · filed 2023-03-31 | ||
| 2021-09-30 | $7.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | -$3.00K derived: sum of 2 quarters · filed 2022-11-14 | $167.00K 10-Q · filed 2022-11-14 | |||
| 2021-06-30 | -$10.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $160.00K 10-Q · filed 2022-08-15 | ||||
| 2021-03-31 | $170.00K 10-Q · filed 2022-05-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |